Abbott stock drops, ABT traders eye earnings after MLK Day shuts Wall Street

New York, Jan 18, 2026, 4:37 PM EST — Market closed.

Abbott shares dipped 1.4% on Friday, ending the day at $121.76.
Trading will resume Tuesday, following Monday’s U.S. market holiday.
All eyes are on Abbott’s earnings report, set for release on Jan. 22.

Abbott Laboratories shares slipped 1.4% to close at $121.76 on Friday, as the healthcare firm entered the holiday break with its next key event just days ahead.

The stock fell for a second day in a row, now trading almost 14% under its 52-week peak. The wider market showed weakness during the session, and Abbott underperformed several major drugmaker rivals. (MarketWatch)

Markets in the U.S. will be closed on Monday for Martin Luther King Jr. Day, extending the holiday and narrowing the time to adjust positions before a packed slate of earnings. This often leads to thinner volumes and sharper moves when trading resumes. (New York Stock Exchange)

Abbott plans to report its fourth-quarter 2025 earnings on Thursday, Jan. 22, ahead of the market open. The company will host a webcasted conference call at 8 a.m. Central time, it said. (Abbott MediaRoom)

Wall Street analysts monitored by Zacks forecast Abbott will post earnings of $1.50 per share — a standard profit metric — on $11.79 billion in revenue. Medical devices are expected to lead growth, with diabetes care standing out within that segment. (Nasdaq)

Abbott launched “Libre Assist” earlier this month, a fresh feature in its Libre app that leverages generative AI to help users understand how their food choices might impact glucose levels. Marc Taub, a vice president at Abbott’s diabetes care division, emphasized that people want more than simple food-logging apps. (Abbott MediaRoom)

The immediate question is straightforward: will Thursday’s report and outlook lure investors back into a stock that’s been sliding? Any guidance that misses expectations, or signals cooling demand in major device categories, might keep the shares under pressure.

Traders can reset their positions starting Tuesday, with focus quickly shifting to Abbott’s earnings report due Jan. 22 before markets open. (Zacks)

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Medtronic advances into 2026 on diabetes spin-off, Hugo system, and steady dividends
January 18, 2026, 4:43 PM EST. Medtronic (MDT) is trading on the prospect that a planned stand-alone spin-off of its diabetes business will sharpen focus on B2B operations and lift margins. Management has signaled the split should close by year-end 2026, reducing exposure to consumer diabetes care, which generated about 8% of revenue but only 4% of operating profit in fiscal 2025. A new growth driver comes from the Hugo robotic-assisted surgery (RAS) system, cleared in the U.S. for urologic procedures. While near-term top-line impact is modest, the device targets an underpenetrated market with long-term potential. Finally, Medtronic boasts a lengthy dividend streak, raising payouts for 48 consecutive years and offering about a 3% forward yield, with the potential to join the Dividend King club after 50 straight raises.